3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Polycystic Ovary Syndrome
9
Motor Activity
7
Prostatic Neoplasms
3
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Insulin Resistance
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Fatigue
1
Diabetes Mellitus, Type 1
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Arthritis, Rheumatoid
1
Anxiety Disorders
1
Interventions
Gemcitabine
78
Cisplatin
55
pembrolizumab
31
Paclitaxel
28
Carboplatin
24
Docetaxel
19
Radiotherapy
17
Mitomycin
16
Doxorubicin
15
atezolizumab
14
BCG Vaccine
14
Nivolumab
13
Cystectomy
12
Filgrastim
11
vinflunine
10
Methotrexate
10
Vinblastine
9
Fluorouracil
9
5-aminolevulinic acid hexyl ester
9
Sunitinib
7
Early Intervention, Educational
7
durvalumab
6
avelumab
6
Taxes
6
Methods
6
Cystoscopy
6
Albumin-Bound Paclitaxel
6
enfortumab vedotin
5
Trastuzumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urinary Bladder Neoplasms
×
High-Intensity Interval Training
×
Clear all
NCT04593862
2024-09-19
BRAVE
University of Alberta
Phase 2
Completed
25 enrolled